TheEdgeResearch
Home / Stocks / LNSR

LENSAR Inc (LNSR)

NASDAQ Healthcare Medical - Devices
$6.92 ▼ -2.19%
Market Cap
$85.0M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.97
52-Wk Range
4.95-12.94
CEO
Nicholas T. Curtis
Country
US
Currency
USD

LENSAR Inc operates in the Medical - Devices industry of the Healthcare sector, headquartered in Orlando, FL, US. The stock last traded at $6.92, down 2.19% on the session, giving a market capitalisation of $85.0M. On trailing twelve-month figures it carries a trailing P/E of 5.45, a net margin of 57.6%. Its beta of 0.97 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
5.45
Price / Sales
1.41
Price / Book
5.71
EV / EBITDA
2.07
Gross margin
48.0%
Operating margin
-13.5%
Net margin
57.6%
Return on equity
—
Debt / equity
0.16
Current ratio
2.39
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
150
IPO date
2020-10-02
Headquarters
Orlando, FL, US
About LENSAR Inc

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Comparable companies

LENSAR Inc is most often compared with the following Healthcare names:

ANIKARAYAVRCRBPCRDFMXCTOWLTPROFRPIDTLSI
More research on LNSR
LNSR technical analysis LNSR TheEdge Score Compare against peers
Open full interactive analysis & DCF →